'Acadia' Think It Really Works? After Two Fails, Phase III Win
Two strikes – and investor suspense – led up to a home run for Acadia Pharmaceuticals Inc., which tweaked the designs of previous, failed Phase III trials and thereby met all endpoints in the latest one with pimavanserin in Parkinson's disease psychosis.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST